Some data on consumption, production and hiring can be estimated using private sources, but inflation remains a blind spot.

A year ago, Pfizer tied a subcutaneous injection of the highest dose of the anti-GDF-15 antibody ponsegromab once every four ...

US News & World Report, a media company specializing in healthcare rankings and consumer advice, revealed its top Medicare ...

The downsides are real, but these aren't deal-breakers. Scaling data AI monetization with free models means owning the full life cycle, be it cost, compliance or execution. With the right strategy, ...

The potential benefits of GLP-1 medications continue to expand. New research has found that the weight loss and diabetes drugs — officially known as glucagon-like peptide 1 receptor agonists — are ...

Pilot study met key 3-month efficacy endpoint with strong statistical significance (p=0.014); Revita-treated patients lost an additional 2.5% total body weight after stopping GLP-1 drugs vs. 10% ...

What’s feeding your hunger? New research suggests that your motivation for eating that second slice of pizza could influence how well you respond to blockbuster GLP-1s like Ozempic and Wegovy. The ...

The duel of the GLP-1 data sets continues this week, with Novo issuing the latest salvo of updates on its oral obesity candidate and an Ozempic head-to-head trial win against another stalwart diabetes ...

Charlotte Lee does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...

The safety and tolerability data were at odds with an earlier phase 1 trial, and not as good as a comparable drug trial result from Eli Lilly. Viking may decide to take VK2735 (oral form) through ...

Viking Therapeutics (NASDAQ:VKTX) lost ~38% in the premarket on Tuesday after announcing that its oral tablet formulation of its GLP-1/GIP dual receptor agonist VK2735 caused up to 12.2% of weight ...